
Potential concerns surrounding GLP-include pancreatitis, pancreatic cancer, colorectal cancer, suicide and other phycological effects, and thyroid cancer.

Potential concerns surrounding GLP-include pancreatitis, pancreatic cancer, colorectal cancer, suicide and other phycological effects, and thyroid cancer.

Jennifer Goldman discusses the importance of collaborative care between providers like endocrinologists, cardiologists, primary care physicians, and pharmacists to manage diabetes and prevent cardiovascular events.

There are approximately 98 million individuals have prediabetes, but approximately only 15 million actually know they have prediabetes.

Semaglutide was found to have effects on glycemia, inflammation, and heart failure outcomes in sub analyses.

Based on these results, tirzepatide could be first medication approved for treatment of obstructive sleep apnea in patients with obesity.

Managing these treatments involves many considerations, including glycemic control and nutrition, among others.

The quadruplet regimen added bortezomib to the current standard of care, which is a triplet regimen of isatuximab, lenalidomide, and dexamethasone for patients with transplant-ineligible, newly diagnosed multiple myeloma (NDMM TI).

Presenters at the American Diabetes Association 84th Scientific Sessions analyzed potential developments in treatment for patients with diabetes and diabetic kidney disease.

There are numerous challenges with cell and gene therapies in oncology, such as accessibility, cost, and prior authorizations, as well as the need for improved education and training within the oncology community.

The study shows that tirzepatide significantly improves secondary outcomes in patients with sleep apnea.

Tim Mok, PharmD, BCOP, BCPS, discusses innovative therapies that are changing the treatment options available for patients with hematologic malignancies.

With improved technology and innovations for diabetes, it is essential for health care providers and health agencies to collaborate to combat rising rates of diabetes.

Niki Shah Vice President of Impact Innovation and Activation at McKesson, previews the 2024 McKesson ideaShare conference.

American Diabetes Association Scientific Sessions speaker Ivan de Araujo emphasizes the importance of the pharmacist’s role in diabetes care and his hopes for the future of care.

Fostering communication and shared terminology is key.

Pharmacy Times will be at McKesson ideaShare 2024 Conference in New Orleans, Louisiana from June 23 to June 26, 2024.

Ryan Haumschild discusses the evolving treatment landscape for patients with multiple myeloma.

Additionally, the high cost of the cell therapy raises concerns for broader access.

Pharmacy Times will be at the American Diabetes Association (ADA) 84th Scientific Sessions in Orlando, Florida from June 21 to June 24, 2024.

Brentuximab vedotin in combination with lenalidomide and rituximab had a favorable safety profile for patients with relapsed/refractory diffuse large B-cell lymphoma.

At ASHP Pharmacy Futures 2024, Mei T. Liu, PharmD, BCPP, highlights the global prevalence and multifaceted nature of depression, its bidirectional relationship with medical conditions, and the need for diverse, evidence-based treatment options.

Lindsey P. Sheehan, PharmD, MPA, MBA, discusses ongoing challenges of diagnosing and treating hepatitis C, emphasizing its increased incidence among younger populations and ongoing low rates of diagnosis.

Individuals with very low- to intermediate-risk myelodysplastic syndromes treated with luspatercept (Reblozyl; Bristol Myers Squibb) achieved improvements in hemoglobulin levels.

Speakers at American Society of Health-System Pharmacists (ASHP) Pharmacy Futures 2024 discuss the significant increase in published clinical literature during and after the COVID-19 pandemic, and the evolving role and reliability of AI tools such as ChatGPT in providing accurate medical information.

At ASHP Pharmacy Futures 2024, Casey Olsen, PharmD, explains that AI can affect patient trust in providers, with implications for the importance of learning to balance use of technology with human elements in clinical settings.

At the ASHP Pharmacy Futures 2024 conference, Scott D. Nelson, PharmD, MS, ACHIP, FAMIA, discusses research showed that although AI models can significantly enhance diagnostic accuracy, they can also exacerbate existing disparities.

Kenneth A. Richman, PhD, discusses the disruptive nature of artificial intelligence (AI) in health care, highlighting both its transformative potential and the ethical considerations of governability and sustainability in its implementation.

The impact of artificial intelligence (AI) on health care is growing, from diagnostics to drug discovery.

Expert discusses the challenges faced by pharmacists in palliative and hospice care.

Guidance for pharmacy technicians as they continue to learn and start their careers.